Data Show That Abbott’s Humira (adalimumab) Reduced The Signs And Symptoms Of Ankylosing Spondylitis Up To Three Years

Abbott announced new data from the open-label extension of the ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS) phase III clinical trial, which showed HUMIRA® (adalimumab) reduced the signs and symptoms of ankylosing spondylitis (AS) for up to three years of treatment among 74 percent of patients tested. AS is a type of arthritis that primarily causes inflammation of the spine and the spinal joints.

More: continued here

Filed under: Immune System / Vaccines on June 19th, 2008